Krystal Biotech, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the results of the 2025 Annual Meeting of Stockholders held by Krystal Biotech, Inc. on May 16, 2025. The report was filed on May 19, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting outcomes.
Material Changes and Voting Results
Stockholders voted on three proposals at the Annual Meeting:
- Proposal One (Election of Class II Directors): Stockholders elected Daniel S. Janney, Dino A. Rossi, and E. Rand Sutherland, M.D. to the Board of Directors for a three-year term.
- Daniel S. Janney: 19,838,511 votes for; 4,134,755 votes withheld.
- Dino A. Rossi: 23,336,879 votes for; 636,387 votes withheld.
- E. Rand Sutherland, M.D.: 23,337,104 votes for; 636,162 votes withheld.
- Proposal Two (Ratification of Auditors): Stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Votes For: 27,723,997
- Votes Against: 14,761
- Abstentions: 5,354
- Proposal Three (Advisory Vote on Executive Compensation): Stockholders approved the compensation of named executive officers for the fiscal year ended December 31, 2024.
- Votes For: 22,543,683
- Votes Against: 1,423,437
- Abstentions: 6,146
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Key Facts for Investor Verification
- Confirmation that KPMG LLP is the appointed auditor for the 2025 fiscal year.
- Verification of the new Board composition following the election of Class II directors.
- Review of the proxy statement for details on the executive compensation package approved by shareholders.
- Analysis of the vote withheld on Daniel S. Janney, which was significantly higher than for other nominees.